First Wave BioPharma Probability of Future Stock Price Finishing Under 3.43
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
First |
First Wave Target Price Odds to finish below 3.43
The tendency of First Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 3.43 after 90 days |
| 0.61 | 90 days | 3.43 | about 99.0 |
Based on a normal probability distribution, the odds of First Wave to stay under $ 3.43 after 90 days from now is about 99.0 (This First Wave BioPharma probability density function shows the probability of First Stock to fall within a particular range of prices over 90 days) . Probability of First Wave BioPharma price to stay between its current price of $ 0.61 and $ 3.43 at the end of the 90-day period is over 95.73 .
Given the investment horizon of 90 days First Wave BioPharma has a beta of -0.27. This usually indicates as returns on the benchmark increase, returns on holding First Wave are expected to decrease at a much lower rate. During a bear market, however, First Wave BioPharma is likely to outperform the market. Additionally First Wave BioPharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. First Wave Price Density |
| Price |
Predictive Modules for First Wave
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as First Wave BioPharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.First Wave Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. First Wave is not an exception. The market had few large corrections towards the First Wave's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold First Wave BioPharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of First Wave within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.77 | |
β | Beta against Dow Jones | -0.27 | |
σ | Overall volatility | 0.69 | |
Ir | Information ratio | -0.23 |
First Wave Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of First Wave for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for First Wave BioPharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| First Wave BioPharma is now traded under the symbol ENTO. Please update your portfolios or report it if you believe this is an error. Report It! | |
| First Wave BioPharma is not yet fully synchronised with the market data | |
| First Wave BioPharma has some characteristics of a very speculative penny stock | |
| First Wave BioPharma has a very high chance of going through financial distress in the upcoming years | |
| First Wave BioPharma currently holds 826.84 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. First Wave BioPharma has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about First Wave's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| First Wave BioPharma currently holds about 1.16 M in cash with (12.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
First Wave Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of First Stock often depends not only on the future outlook of the current and potential First Wave's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. First Wave's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 336.3 K | |
| Cash And Short Term Investments | 3.7 M |
First Wave Technical Analysis
First Wave's future price can be derived by breaking down and analyzing its technical indicators over time. First Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of First Wave BioPharma. In general, you should focus on analyzing First Stock price patterns and their correlations with different microeconomic environments and drivers.
First Wave Predictive Forecast Models
First Wave's time-series forecasting models is one of many First Wave's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary First Wave's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about First Wave BioPharma
Checking the ongoing alerts about First Wave for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for First Wave BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| First Wave BioPharma is now traded under the symbol ENTO. Please update your portfolios or report it if you believe this is an error. Report It! | |
| First Wave BioPharma is not yet fully synchronised with the market data | |
| First Wave BioPharma has some characteristics of a very speculative penny stock | |
| First Wave BioPharma has a very high chance of going through financial distress in the upcoming years | |
| First Wave BioPharma currently holds 826.84 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. First Wave BioPharma has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about First Wave's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| First Wave BioPharma currently holds about 1.16 M in cash with (12.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |